Toxicity Outcomes of Simultaneous Integrated Boost in Adjuvant Breast Radiotherapy Acronym

Toxicity Outcomes of Simultaneous Integrated Boost as Part of Adjuvant Radiotherapy in Breast Cancer Patients After Breast-Conserving Surgery

This prospective study systematically evaluates toxicity outcomes in breast cancer patients treated with adjuvant radiotherapy using the simultaneous integrated boost (SIB) technique after breast-conserving surgery. The aim is to monitor acute and late treatment-related side effects during implementation of this radiotherapy approach and to compare institutional toxicity outcomes with published data in the literature.

Breast cancer patients undergoing breast-conserving surgery are treated with adjuvant radiotherapy using either standard fractionation or hypofractionation combined with a simultaneous integrated boost (SIB) to the tumor bed. This prospective study includes systematic collection and grading of acute and late radiation-related toxicity outcomes in order to evaluate the safety of the implemented protocol and to assess whether toxicity rates are comparable to those reported in published clinical studies. The results will support optimization and quality assurance of the radiotherapy technique in routine clinical practice.

Inclusion Criteria:

• Female patients with histologically confirmed breast cancer
• Status post breast-conserving surgery (lumpectomy)
• Planned adjuvant whole-breast radiotherapy with simultaneous integrated boost (SIB) to the tumor bed
• Age ≥ 18 years
• Ability to provide informed consent

Exclusion Criteria:

• Prior radiotherapy to the breast or thoracic region
• Mastectomy (no breast-conserving surgery)
• Pregnancy or breastfeeding
• Inability to complete planned radiotherapy or follow-up assessments